1. Home
  2. LOAN vs GRML Comparison

LOAN vs GRML Comparison

Compare LOAN & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.43

Market Cap

48.2M

Sector

Real Estate

ML Signal

HOLD

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.24

Market Cap

51.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LOAN
GRML
Founded
1989
N/A
Country
United States
United States
Employees
N/A
5
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
51.5M
IPO Year
1999
2022

Fundamental Metrics

Financial Performance
Metric
LOAN
GRML
Price
$4.43
$0.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.2K
3.5M
Earning Date
04-16-2026
05-13-2026
Dividend Yield
10.06%
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$8,666,307.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$40.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$0.21
52 Week High
$5.85
$0.55

Technical Indicators

Market Signals
Indicator
LOAN
GRML
Relative Strength Index (RSI) 61.14 36.76
Support Level $4.41 N/A
Resistance Level $4.48 $0.34
Average True Range (ATR) 0.08 0.04
MACD 0.01 -0.00
Stochastic Oscillator 86.96 34.70

Price Performance

Historical Comparison
LOAN
GRML

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: